logo
Plus   Neg
Share
Email

Cellectar Biosciences Skyrockets On Positive Data In Cancer Trial

Clinical stage biopharmaceutical company Cellectar Biosciences (CLRB), said a patient with a rare type of cancer that begins in the white blood cells, showed a 94% reduction in tumor burden and complete resolution in four of five targeted tumor masses, in a mid-stage cancer study. CLRB is currently trading up 1365.95% at $10.98.

Key takeaways from the company's Press Release

* Prior to study enrollment, this 67-year-old female patient was diagnosed with Waldenstrom macroglobulinemia (a rare type of cancer that begins in the white blood cells) had received two lines of multi-drug therapy with the most recent treatment achieving a best response of disease progression

*As part of Cellectar's Phase 2 study in hematologic cancers, the patient received a single 25mCi/m2 dose of the company's investigational drug CLR 131 over a 30-minute infusion period. On day 52 post infusion, a CT scan showed a >50% reduction in tumor volume and was classified as a partial response.

*Based on this initial response and additional clinical factors, the treating physician administered a second dose of CLR 131 on day 123. A CT scan taken 64 days after the second dose, showed a 94% overall reduction in tumor burden and complete resolution in four of five targeted tumor masses. The total targeted tumor mass shrank from approximately 4700mm2 prior to the first CLR 131 infusion to approximately 500mm2 at last reading.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Airbnb has introduced few new rules to control parties and nuisances amidst the backlash the service received after the Halloween shooting at an Airbnb rental in a San Francisco. San Francisco-based Airbnb said it is banning "open invite" parties at all of its accommodations. The company is also banning... The U.S. Food and Drug Administration has approved three generic versions of Novartis' Gilenya capsule for treating relapsing forms of multiple sclerosis. "Approving safe and effective generics so patients have more treatment options continues to be a priority for the FDA," said Janet Woodcock, director... Shares of Upscale furniture chain RH (RH) are on a tear, on the heels of an upbeat annual forecast. Today, the stock set a new all-time high of $239.88.The stock is up more than 20% from its Dec 3 opening price of $196.66, and currently trading at $237.8, and nearly three-times its 52-week low of $84.11....
Follow RTT
>